{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307328","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.105851+00:00","generated_at":"2026-06-21T03:18:58.405421+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Nurix amends bylaws to comply with new universal proxy rules and DGCL updates","bullets":["Revised advance notice bylaws require additional disclosures from nominating stockholders and restrict number of nominees to directors up for election.","Added compliance requirements for stockholders using universal proxy rules (Rule 14a-19), including certification and evidence submission 5 business days before meeting.","Updated meeting conduct: presiding officer may set extra attendance procedures; proxy card color must be non-white for soliciting stockholders.","Added emergency bylaw provision to allow board or committee quorum during situations preventing normal meeting requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307328","json":"https://secwatch.observer/filing/0001193125-22-307328.json","markdown":"https://secwatch.observer/filing/0001193125-22-307328.md","text":"https://secwatch.observer/filing/0001193125-22-307328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522307328/0001193125-22-307328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522307328/d410964d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:18:58.405421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6836b6b031c2d84c8ba7f3cbe267caa8e1ffa80","claim":"Nurix Therapeutics, Inc.: Amended and restated bylaws to update stockholder meeting procedures, advance notice requirements, universal proxy rules, and other provisions to conform to DGCL amendments and SEC universal proxy rules (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Nurix Therapeutics, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522307328/0001193125-22-307328-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-15"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}